Latest From Biocartis NV
€24m loan from the European Investment Bank with match funding will progress Phase IIb antifungal Olorofim in invasive aspergillosis. CFO Ralf Schmid goes into details with Scrip.
The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.
Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance or Financing. This month’s column covers deals announced in November 2017.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Biocartis NV
- Senior Management
Herman Verrelst, CEO
Ewoud Weten, CFO
Hilde Eylenbosch, MD, Chief Commercial Officer
Benoit Devogelaere, PhD, CTO
- Contact Info
Phone: (41) 15 632 600
Generaal De Wittelaan
Mechelen , 2800
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.